05/25/23 5:01 PMNasdaq : MOLN conferencesclinical triallow floatMolecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual MeetingMP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combinationRHEA-AIneutral
05/16/23 4:00 PMNasdaq : MOLN conferenceslow floatMolecular Partners to Participate in RBC Capital 2023 Global Healthcare ConferenceMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Patrick Amstuts, ChiefRHEA-AIneutral
05/11/23 4:00 PMNasdaq : MOLN earningslow floatInterim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio StrategyMP0533: Phase 1 trial of MP0533 for AML ongoing; initial recruitment is progressing well, and site expansion is ongoing; initial clinical results on track for Q4 2023 MP0317: Highest dose cohort (Q3W, 10mg/kg) now enrolling; clinical update at ASCO Radio DARPin Therapy (RDT): Presented preclinicalRHEA-AIneutral
04/14/23 1:00 AMNasdaq : MOLN conferencesclinical triallow floatMolecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACRTargeted radionuclide delivery platform strengthened by new safety and mechanistic data Data includes review of high tumor penetration potential of DARPins and reduced kidney accumulation via DARPin engineering New findings will be shared on April 18, 2023, at the American Association for CancerRHEA-AIneutral
04/04/23 11:44 AMNasdaq : MOLN low floatMolecular Partners Announces Shareholders Approve All Board Proposals at the Annual General MeetingMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the shareholders of theRHEA-AIneutral
03/13/23 9:30 AMNasdaq : MOLN low floatMolecular Partners Publishes Invitation to Annual General Meeting 2023Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today published the invitation to the AnnualRHEA-AIneutral
03/09/23 4:00 PMNasdaq : MOLN low floatMolecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64thRHEA-AIneutral
03/02/23 4:00 PMNasdaq : MOLN low floatMolecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care ConferenceMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing itsRHEA-AIneutral
02/28/23 1:15 AMNasdaq : MOLN clinical triallow floatMolecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy PlatformProprietary Radio DARPin Therapy Platform designed to deliver high amount of radioactivity to the tumor while maintaining low accumulation in other tissues Data reveal engineering approach to significantly reduce kidney accumulation of DARPin-based radiotherapeutic candidates to potentially expandRHEA-AIneutral
02/10/23 1:00 AMNasdaq : MOLN conferenceslow floatMolecular Partners to Present at SVB Leerink Global Healthcare ConferenceMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief ExecutiveRHEA-AIneutral